NEW YORK (GenomeWeb News) – Massachusetts-based BG Medicine has acquired exclusive, worldwide rights from ACS Biomarker to develop and commercialize a clinical diagnostic test for acute atherothrombosis, the companies announced yesterday.
Scientists at the Cardiovascular Research Institute Maastricht in the Netherlands discovered the biomarker, which BG plans to develop into a test to diagnose transient blockages that cause stroke-like symptoms, coronary artery blockages, and other heart attack and stroke precursors.
In exchange for the license, ACS Biomarker will receive from BG milestone payments as well as royalties on net sales and sublicensing income on any commercialized products.
ACS Biomarker was founded to develop and commercialize cardiovascular biomarkers discovered at CARIM.
Atherothrombosis results from ruptured arterial plaques, which send deposits hurtling through the arteries, where they can cause blood clotting and, ultimately, heart attacks or strokes. But the condition often goes unnoticed until it manifests itself as a life-threatening cardiovascular event.
The latest deal comes after a May 2007 agreement between the two companies in which BG Medicine acquired the rights to ACS Biomarker’s biomarker for congestive heart failure.